Table 2 Univariable and multivariable analysis to identify the risk factors for events.

From: Nationwide cohort observational study on the safety and efficacy of COVID-19 vaccination in patients with moyamoya disease

 

Univariable analysis

Multivariable analysis

OR

95% CI

p-value

OR

95% CI

p-value

Age

 20–29

Reference

Reference

 30–39

2.21

0.74

6.58

0.157

1.56

0.52

4.71

0.430

 40–49

3.46

1.25

9.61

0.017

2.73

0.97

7.66

0.057

 50–59

4.02

1.47

11.01

0.007

3.29

1.18

9.12

0.022

60 ≤ 

6.44

2.38

17.47

 < 0.001

5.20

1.89

14.29

0.001

Sex

Male

Reference

Reference

 Female

0.69

0.54

0.87

0.002

0.64

0.50

0.82

 < 0.001

BMI (kg/m2)

 < 18.5

2.07

1.25

3.42

 < 0.001

2.00

1.18

3.41

0.011

 18.5–22.9

Reference

e

  

Referenc

   

 23.0–24.9

0.90

0.70

1.17

0.442

0.83

0.64

1.09

0.177

 25 ≤ 

0.68

0.43

1.09

0.106

0.78

0.48

1.26

0.307

BP (mmHg)

 Normal

Reference

    

 Elevated

1.00

0.68

1.45

0.983

    

 Stage 1 HTN

1.06

0.80

1.40

0.703

    

 Stage 2 HTN

1.33

0.91

1.94

0.144

    

FBS (mg/dl)

 < 100

Reference

    

 100–126

1.19

0.92

1.53

0.179

    

 126 ≤ 

1.32

0.92

1.88

0.129

    

Revascularization

 -

Reference

Reference

 + 

0.36

0.19

0.68

0.002

0.38

0.21

0.70

0.008

Previous stroke

 -

Reference

Reference

 + 

2.54

1.92

3.35

 < 0.001

1.96

1.47

2.60

 < 0.001

Vaccination

 -

Reference

Reference

 + 

0.17

0.13

0.21

 < 0.001

0.17

0.13

0.22

 < 0.001

COVID19 infection

 -

Reference

Reference

 + 

2.43

1.18

5.02

0.017

2.28

1.07

4.87

0.034

  1. BMI, body mass index; BP, blood pressure; CI, confidence interval; FBS, fasting blood sugar; HTN, hypertension; OR, odds ratio.
Back to article page